10 things I've learned from 10 years of investing

Finding and holding great companies like Xero Limited (ASX: XRO) and Pushpay Holdings Ltd (ASX: PPH) doesn't come without a few losers along the way.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I've been investing for over a decade now. It has been a great ride and my approach has changed significantly over the years.

Here are 10 of the most useful things I've learned that drive the way I invest today.

1. It pays to be a careful observer of the world around you

In a world of increasing complexity some of the best (and easiest) investing ideas come from simply observing how things are changing around you.

2. "Basically, the single-most-important decision in evaluating a business is pricing power"

This single Buffett quote cuts to the heart of the investing problem more than almost any other. Pricing power comes from having a competitive advantage which can drive above average returns for decades to come.

3. Some risks aren't worth taking

Commodity price risk, turn around risk and public policy risk are three simple risks that need a lot of attention and can be easily avoided. This is better left to smart people with the time to burn.

4. The best investments can break all the rules

Some of my best investments, like Xero Limited (ASX: XRO) and Pushpay Holdings Ltd (ASX: PPH), have come from companies that break the traditional investment rules. These 'Rule Breaker' investments often look expensive but have strong advantages that mean they can keep winning.

5. Personal finance is more personal than it is finance

There are 1001 ways to invest your money. Very few will fit with your needs, personality and risk tolerance. Once you figure out the approach that works for you, you will be on your way to success.

6. To know when to sell you must know why you bought

I still find selling the most difficult part of the investing. Knowing when to sell is simplified by having a strong understanding of why you bought and when that thesis is broken.

7. If you don't understand a company, don't buy it

I've avoided a lot of lousy investments over the years because I just didn't 'get' them. In every case I felt dumb. However, most have since under performed or collapsed. Complex business structures have a nasty habit of masking a significant shortcomings and are often best avoided.

8. Foxes tend to be better investors than hedgehogs

There is an expression that "the fox knows many things, but the hedgehog knows one big thing."

Like the fox, the most successful investors I know read widely, actively look for different viewpoints and can see the world through different lenses.

9. "Make your portfolio reflect your best vision for our future"

This quote from The Motley Fool co-founder David Gardner forces me to think long term and to consider how a company will fit into my view of the world in 5, 10 or 20 years time.

10. Compounding is the holy grail and not just for investing

Perhaps the most important lesson after 10 years is the realisation that success, not just in investing, but life, comes from compounding.

We should compound everything that is great: knowledge, fitness, the skills we value and deep personal relationships. The process can feel painfully slow. However incremental gains, year-after-year, can grow into something incredible.

Regan Pearson owns shares of PUSHPAY FPO NZX and Xero.

You can follow him on Twitter @Regan_Invests.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of PUSHPAY FPO NZX. The Motley Fool Australia owns shares of Xero. The Motley Fool Australia has recommended PUSHPAY FPO NZX. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »